AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
Year-end report discusses combination therapy’s Mechanism of Action activating both innate and adaptive immune responsesOCALA, Fla., Feb. 05, 2026 (GLOBE...